Today: 5 February 2026
Subscribe
Browse Category

Biotech News News 14 January 2026 - 20 January 2026

AbbVie stock slips as traders watch Epkinly data and the next earnings clock

AbbVie stock slips as traders watch Epkinly data and the next earnings clock

New York, January 20, 2026, 13:13 ET — Regular session underway Shares of AbbVie Inc slipped 82 cents, or 0.4%, to $213.53 in early afternoon trading on Tuesday, fluctuating between $210.00 and $214.23. Around 2.9 million shares changed hands. The tick-by-tick move was modest, yet AbbVie’s shares have grown quick to respond to drug data. Investors are grappling with the…
20 January 2026
·····
ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

New York, January 20, 2026, 12:42 ET — Regular session ImmunityBio, Inc. shares climbed roughly 24% to $6.82 by midday Tuesday after the company revealed the U.S. Food and Drug Administration provided guidance that could pave the way for a resubmission of its bladder cancer drug ANKTIVA. Earlier, the stock hit $7.97, fluctuating between $4.94 and $7.97 on about 159…
20 January 2026
····
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

New York, Jan 18, 2026, 11:03 EST — Market closed AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two…
18 January 2026
·······
Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

New York, Jan 18, 2026, 07:03 (EST) — Market closed ImmunityBio’s IBRX shares ended Friday at $5.52, jumping roughly 40% following a series of company updates that attracted momentum traders. Trading volume surged past 182 million shares. This shift is key as ImmunityBio heads into a shortened week, aiming to convert early interest in its first cancer drug into consistent…
18 January 2026
·····
ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

NEW YORK, Jan 18, 2026, 05:13 EST — Market closed ImmunityBio shares jumped sharply on Friday following a series of updates, including early sales figures for its approved bladder-cancer drug and new data from its development pipeline. The stock closed the day up 39.75% at $5.52 and later climbed to $6.04 in after-hours trading. (Yahoo Finance) This move is significant…
18 January 2026
····
ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

New York, Jan 17, 2026, 06:10 EST — Markets have closed for the day. Shares of ImmunityBio Inc (IBRX.O) surged almost 40% on Friday following a strong boost in preliminary sales for its bladder cancer treatment ANKTIVA, alongside fresh trial updates. The stock finished at $5.52, marking a 39.9% gain, after swinging between $4.09 and $6.44 on heavy volume of…
17 January 2026
·····
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

New York, January 16, 2026, 14:57 EST — Regular session Shares of BridgeBio Pharma Inc edged up 0.5% to $76.66 Friday afternoon, following the announcement of a $550 million convertible notes sale. The stock swung between $75.87 and $78.12, with roughly 5.9 million shares changing hands. (BridgeBio Investor Relations) This financing matters because it reshapes BridgeBio’s balance sheet in one…
16 January 2026
·····
ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

New York, January 16, 2026, 05:00 (EST) — Premarket ImmunityBio, Inc. shares jumped roughly 32% to $3.95 in premarket trading Friday following the biotech’s report of a steep rise in preliminary 2025 product revenue. The company also highlighted recent regulatory approvals in Saudi Arabia. (Business Wire) The update offers investors an early glimpse of how quickly ANKTIVA is growing commercially,…
16 January 2026
····
Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

New York, January 14, 2026, 14:54 EST — During regular session Shares of Praxis Precision Medicines jumped roughly 8% on Wednesday, bucking the weaker trend in the broader market. By mid-afternoon, the Nasdaq-listed biotech was trading at $303.23, up $22.40. The move came after Praxis announced late Tuesday it hired epilepsy expert Dr. Orrin Devinsky for a new head of…
14 January 2026
····
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

New York, Jan 14, 2026, 13:09 EST — Regular session Cogent Biosciences shares rose about 8% on Wednesday, lifting the biotech’s stock toward recent highs as investors focused on a near-term U.S. regulatory checkpoint for its lead drug candidate, bezuclastinib. The stock was up at $38.17, after trading between $35.17 and $38.34. The move matters because Cogent’s story is now…
14 January 2026
·····
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

New York, January 14, 2026, 13:09 EST — Regular session underway. Shares of Viking Therapeutics climbed roughly 11% on Wednesday, rising from a $30.44–$34.08 range to $34.06 by 1:09 p.m. EST. The move came amid renewed deal speculation in obesity treatments. CEO Brian Lian noted that interest was “broader than is visible” with more players “circling around the space.” Analysts…
14 January 2026
····
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

New York, Jan 14, 2026, 12:55 (EST) — Regular session Shares of Edgewise Therapeutics Inc (EWTX.O) were up 10.6% at $27.59 by 12:55 p.m. EST on Wednesday after the drug developer laid out a 2026 schedule for clinical readouts and trial starts across its muscle-disease and cardiac pipeline. The move matters because Edgewise is still pre-commercial, and its valuation hangs…
14 January 2026
·····
1 2 3 4 … 12

Stock Market Today

  • Super Bowl Prediction Markets Sidestep Sports Betting Bans in California
    February 5, 2026, 7:44 AM EST. Prediction market platforms like Kalshi and Polymarket enable sports wagering in states banning traditional sportsbooks, including California. These platforms let users trade event contracts rather than place conventional bets, creating a legal gray area as they avoid acting as the 'house' while charging fees. Kalshi reported $161 million in Super Bowl market trading volume, a sixfold rise from last year. Critics question if these contracts amount to repackaged gambling, referencing California's century-old law prohibiting betting on sports. Industry advocates argue these markets are federally regulated financial exchanges distinct from traditional sportsbooks, allowing traders to buy and sell positions until outcomes settle. Legal experts suspect courts will allow this activity to continue for years amid regulatory uncertainty.
Go toTop